This Article contains typographical errors.
In the Results section under subheading ‘In vivo anticancer activity against Ehrlich ascites Carcinoma (EAC)’
“The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 71.75% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.”
should read:
“The experimental results showed that 3-AWA reduced Ehrlich ascites carcinoma by 70.5% at 10 mg/kg intraperitoneal dose in comparison to the tumor growth inhibition of 87.4% in 5-FU (22 mg/kg i.p.) treated group.”
In the legend of Table 1
“Values are mean ± S.E. (n = 7, 10 for control).”
should read:
“Values are mean ± S.E. (n = 8).”
Additional information
The online version of the original article can be found at 10.1038/srep18800
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Rasool, R., Rah, B., Amin, H. et al. Correction: Corrigendum: Dual modulation of Ras-Mnk and PI3K-AKT-mTOR pathways: A Novel c-FLIP inhibitory mechanism of 3-AWA mediated translational attenuation through dephosphorylation of eIF4E. Sci Rep 6, 21054 (2016). https://doi.org/10.1038/srep21054
Published:
DOI: https://doi.org/10.1038/srep21054
